Chunumunu/iStock via Getty Images
Kyverna Therapeutics, affectionately known as KYTX, has once again pushed the envelope by upsizing its proposed initial public offering – this time to a staggering $297M from its initial target of $200M.
In the latest SEC filing, Kyverna revealed its ambitious plan to offer 14.5M shares priced in the range of $20 to $21, with the potential to raise the aforementioned $297M if the stars aligned at the midpoint. To sweeten the deal, underwriters would be granted an option to purchase up to 2.18M additional shares to cover over-allotments, adding a cherry on top of this unprecedented offering.
In a heartbeat, Kyverna aims to list its shares on Nasdaq, proudly touting the symbol KYTX. The dream team of JP Morgan, Morgan Stanley, Leerink Partners, and Wells Fargo Securities are stepping in as the bookrunners.
Plunging into its lead program, KYV-101, a CD19 CAR T-cell therapy licensed from the esteemed National Institutes of Health, Kyverna is racing ahead. KYV-101 is currently navigating Phase 1 testing for lupus nephritis and systemic sclerosis, while simultaneously tackling Phase 2 testing for myasthenia gravis and multiple sclerosis.
Brave New Horizons
The brave new horizon beckons, and Kyverna Therapeutics is leading the charge. The audacious upsized IPO to $297M, from a more modest $200M, speaks volumes about investor confidence in the biotech company’s potential. KYTX’s bold steps in the IPO market are akin to a fledgling bird taking the fearless leap out of the nest, fueled by the unyielding belief in its wings and the open sky above.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
